Latest From NeuroVia Inc.
Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.
This week's roundup includes a handful of promotions by Eli Lilly, and various board and high-level appointments by companies including Kiadis Pharma, Aeterna Zentaris, Dermavant Sciences and Pliant Therapeutics.
Complexa topped the list of recent venture capital financings with a $62m Series C round, followed by Evelo and Kezar with $50m Series B rounds and LogicBio with a $45m Series B.
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- NeuroVia Inc.
- Senior Management
Giovanni Ferrara, Interim Pres. & CEO
Masoud Mokhtarani, MD, CMO
John Henderson, MD, Chief Dev. Officer
Catherine Norris, Dir, Clin. Operations
- Contact Info
Phone: (415) 870-6967
1700 Owens St.
San Francisco , CA 94158
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.